期刊
ANTICANCER RESEARCH
卷 39, 期 12, 页码 6635-6643出版社
INT INST ANTICANCER RESEARCH
DOI: 10.21873/anticanres.13878
关键词
Glioblastoma; tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-secreting human mesenchymal stem cells; MSC-TRAIL; compound C; gene therapy
类别
资金
- Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) - Ministry of Health and Welfare, Republic of Korea [HI6C012, HI18C2148]
Background/Aim: Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) triggers apoptosis of cancer cells and, when used in combination with other anticancer drugs, is regarded as an effective strategy for anticancer treatment. In this study, we investigated the efficacy of combination treatment with TRAIL-secreting human mesenchymal stem cells (MSC-TRAIL) and compound C, an AMP-activated protein kinase (AMPK inhibitor), on glioblastoma. Materials and Methods: The anticancer effect using MSC-TRAIL and compound C on glioma was evaluated in vitro and on in vivo models. Results: Combination treatment of MSC-TRAIL and compound C increased apoptosis by enhancing expression of B-cell lymphoma 2 (BCL2)-associated X protein (BAX) and reducing that of anti-apoptotic proteins cellular FLICEinhibitory protein (FLIP), X-linked inhibitor of apoptosis (XIAP), and BCL2 in glioma. In addition, MSC-TRAIL and compound C combination increased caspase-3 cleavage and apoptotic cells in a mouse glioma model compared with the group treated with the agents alone. Conclusion: Our results suggest that MSC-TRAIL and compound C are a novel combination for treatment of glioma.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据